Last reviewed · How we verify
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
The purpose of this study is to determine if VT-122 provides a clinical benefit when added to Sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Details
| Lead sponsor | Vicus Therapeutics |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 20 |
| Start date | 2010-12 |
| Completion | 2016-04 |
Conditions
- HCC
Interventions
- Sorafenib
- VT-122 (propranolol plus etodolac)
- Placebo
Primary outcomes
- failure free survival — 6 months
Countries
United States